...
首页> 外文期刊>BMC Nephrology >Transitional cell carcinoma involving graft kidney in a kidney transplant recipient: a case report
【24h】

Transitional cell carcinoma involving graft kidney in a kidney transplant recipient: a case report

机译:涉及肾移植受体接枝移植肾的过渡细胞癌:案例报告

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background Kidney transplantation (KT) is the treatment option for patients with end stage renal disease (ESRD) to prolong survival and improve quality of life. Although the use of potent immunosuppressive agents increases graft survival in kidney transplantation recipients (KTRs), it may lead to the development of malignancy, including transitional cell carcinoma (TCC). TCC developing in the pelvis of graft kidney is very rare in KTRs. Case Presentation A 40-year-old male visited hospital with complaints of nausea, vomiting and gross hematuria. Eleven years ago, he was diagnosed ESRD of unknown origin, and received a living related KT from his father 1 year later. Radiologic findings showed a huge polypoid mass in the pelvis of graft kidney with pelvo-calyceal dilation and a 3.3?cm-sized nodule in aortocaval chain and a 2.5?cm-sized nodule in right iliac chain as TCC stage IV. Sonography-guided percutaneous needle biopsy of pelvis mass in the graft kidney revealed a low grade urothelial cell carcinoma. Radical graft nephroureterectomy was performed and histopathological diagnosis confirmed as a low grade urothelial carcinoma of graft pelvis and ureter lumen, which invaded to perirenal fat and renal parenchyma with lymphovascular presence (T3Nx). The patient started with adjuvant concurrent chemo-radiation therapy and returned to regular hemodialysis. Conclusions We report a rare case of TCC in the pelvis of graft kidney with already advanced disease at diagnosis in a young KTR. For the early diagnosis of TCC in KTRs, exposure history to Chinese herb or analgesics should be investigated before KT and high risk population in KTRs should be tightly performed regular postoperative surveillance for TCC and considered of less calcineurin inhibitor-based immunosuppressant protocol.
机译:背景技术肾移植(KT)是延长生存和提高生活质量的患者患有末期肾病(ESRD)的治疗选择。虽然使用有效的免疫抑制剂增加肾移植受者(KTR)的移植物存活,但它可能导致恶性肿瘤的发育,包括过渡性细胞癌(TCC)。在嫁接肾脏的骨盆中发育的TCC在KTR中非常罕见。案例介绍一家40岁的男性访问过的医院,抱怨恶心,呕吐和血尿总血尿。十一年前,他被诊断出来的未知来源,并在1年后从他的父亲接受了与生活相关的KT。放射学发现在接枝肾的骨盆中显示出巨大的息肉质量,具有骨盆 - 沟槽扩张的3.3℃,右髂骨链中的3.3Ω·尺寸的结节,作为TCC阶段IV。继承引导的移植肾上骨盆质量的经皮针活检显示出低级尿路上皮细胞癌。进行激进的接枝肾功能切除术,并确诊为接枝骨盆和输尿管腔的低级尿路上皮癌,侵入肝癌(T3NX)侵入肝癌的低级尿路上皮癌。患者开始佐剂并发化疗疗法,并恢复到常规血液透析。结论我们在年轻KTR诊断中报告了患有患有移植肾的骨盆中的TCC含量罕见的TCC病例。对于KTR中TCC的早期诊断,应在KTR和高危人群中调查用于中药或镇痛药的暴露史,应严格对TCC定期进行,并考虑钙素抑制剂的免疫抑制剂方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号